Pharma BD Deal Intelligence

Bayer AG / Onyx Pharmaceuticals, Inc.

2011 · Co-Development · $160M · Complete

Bayer and Onyx restructured their global oncology collaboration: Bayer gained sole decision-making for regorafenib in exchange for $160M cash settlement and royalty on regorafenib. Bayer also bought out Onyx's Japan Nexavar royalty rights.

Did it work? Outcome assessment

Assessment window: 10yr post-close.

Key facts

• Announced Oct 12, 2011
• Closed Dec 01, 2011
• Deal value $160M
• Deal type Co-Development
• Therapeutic area Metastatic colorectal cancer, GIST, HCC, RCC
• Indications Metastatic colorectal cancer, GIST, HCC, RCC
• Key assets Regorafenib (DAST); Nexavar (sorafenib)
• Mechanism Multi-kinase inhibitors (VEGFR, PDGFR, KIT, RAF)

← Browse all deals  ·  How we score deals